Biopharmaceutical company Ipsen (Euronext Paris:IPN) (ADR:IPSEY) announced on Thursday that it has licensed ex-US rights to Day One Biopharmaceuticals' (Nasdaq:DAWN) tovorafenib for paediatric low-grade glioma (pLGG), the most common form of childhood brain cancer.
Tovorafenib is FDA-approved for relapsed or refractory pLGG with BRAF alterations, a condition affecting over half of pLGG cases globally. The drug addresses an unmet need for targeted treatments outside the United States.
Under the agreement Day One will receive USD111m upfront, including USD71m cash and USD40m equity investment, plus up to USD350m in milestones and tiered double-digit royalties.
Ipsen will be responsible for the regulatory and commercial activities for tovorafenib in all territories outside of the United States.
Day One will maintain exclusive global development and US commercial rights for tovorafenib.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval